These findings suggest that targeting B-Raf with small-molecule inhibitors like Sorafenib may be a viable therapeutic strategy to mitigate cyst expansion in ADPKD [135]. This evidence concerns the gene BRAF and autosomal dominant polycystic kidney disease.